ANI Pharmaceuticals, Inc. (ANIP)
- Previous Close
72.56 - Open
72.00 - Bid 69.87 x 100
- Ask 70.52 x 100
- Day's Range
70.14 - 73.50 - 52 Week Range
52.50 - 73.72 - Volume
633,672 - Avg. Volume
368,153 - Market Cap (intraday)
1.565B - Beta (5Y Monthly) 0.56
- PE Ratio (TTM)
-- - EPS (TTM)
-1.04 - Earnings Date May 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
81.88
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. It markets, sells, and distributes its products through wholesalers, retail market chains, distributors and specialty pharmacies, group purchasing organizations, specialty pharmacies, hospitals, clinics, and physicians. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
www.anipharmaceuticals.com897
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: ANIP
View More
Performance Overview: ANIP
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ANIP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ANIP
View MoreValuation Measures
Market Cap
1.57B
Enterprise Value
2.06B
Trailing P/E
--
Forward P/E
11.68
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.28
Price/Book (mrq)
3.88
Enterprise Value/Revenue
3.36
Enterprise Value/EBITDA
32.69
Financial Highlights
Profitability and Income Statement
Profit Margin
-3.02%
Return on Assets (ttm)
0.83%
Return on Equity (ttm)
-4.18%
Revenue (ttm)
614.38M
Net Income Avi to Common (ttm)
-20.15M
Diluted EPS (ttm)
-1.04
Balance Sheet and Cash Flow
Total Cash (mrq)
151.17M
Total Debt/Equity (mrq)
147.17%
Levered Free Cash Flow (ttm)
28.57M
Research Analysis: ANIP
View MoreResearch Reports: ANIP
View MoreRaising target price to $74.00
ANI PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $74.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetLowering target price to $72.00
ANI PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $72.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetRaising target price to $73.00
ANI PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $73.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetLowering target price to $66.00
ANI PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $66.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice Target